Sequoia Financial Advisors LLC Grows Stock Position in Bristol Myers Squibb Company $BMY

Sequoia Financial Advisors LLC boosted its position in shares of Bristol Myers Squibb Company (NYSE:BMY) by 6.9% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 179,874 shares of the biopharmaceutical company’s stock after purchasing an additional 11,558 shares during the period. Sequoia Financial Advisors LLC’s holdings in Bristol Myers Squibb were worth $10,364,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. Northwestern Mutual Investment Management Company LLC raised its stake in shares of Bristol Myers Squibb by 0.3% in the 4th quarter. Northwestern Mutual Investment Management Company LLC now owns 65,046 shares of the biopharmaceutical company’s stock valued at $3,509,000 after purchasing an additional 172 shares in the last quarter. KCM Investment Advisors LLC increased its position in Bristol Myers Squibb by 0.8% in the fourth quarter. KCM Investment Advisors LLC now owns 20,871 shares of the biopharmaceutical company’s stock worth $1,126,000 after buying an additional 174 shares during the period. Sandy Cove Advisors LLC lifted its stake in Bristol Myers Squibb by 4.7% in the second quarter. Sandy Cove Advisors LLC now owns 3,932 shares of the biopharmaceutical company’s stock valued at $227,000 after buying an additional 176 shares during the last quarter. Investment Research Partners LLC boosted its holdings in shares of Bristol Myers Squibb by 1.4% during the fourth quarter. Investment Research Partners LLC now owns 13,134 shares of the biopharmaceutical company’s stock valued at $708,000 after acquiring an additional 179 shares during the period. Finally, REAP Financial Group LLC boosted its holdings in shares of Bristol Myers Squibb by 26.1% during the fourth quarter. REAP Financial Group LLC now owns 879 shares of the biopharmaceutical company’s stock valued at $47,000 after acquiring an additional 182 shares during the period. Institutional investors and hedge funds own 76.41% of the company’s stock.

Trending Headlines about Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Positive Phase 2 results for arlo-cel in heavily pretreated multiple myeloma strengthen Bristol Myers Squibb’s cell-therapy pipeline and could support future growth if the treatment advances successfully. Bristol Myers Squibb Reports Positive Phase 2 Results for Arlo-cel
• Positive Sentiment: An update from a long-term psoriasis study provides additional data for investors evaluating Sotyktu and Bristol Myers Squibb’s ability to expand its growth-brand portfolio. Bristol Myers Squibb’s Long-Term Psoriasis Study
• Positive Sentiment: Analysts continue to cite momentum from BMY’s growth brands and pipeline progress. Sector concerns following safety issues in a Novartis CAR-T program may also improve the relative appeal of Bristol Myers Squibb’s cell-therapy efforts, although this is not a direct change to BMY’s fundamentals. Could Bristol-Myers Squibb Outperform Novartis?
• Neutral Sentiment: Scotiabank maintained its Hold rating, suggesting the current valuation and outlook do not yet justify a stronger bullish view. Scotiabank Keeps Its Hold Rating
• Neutral Sentiment: Recent coverage focused on BMY’s market underperformance rather than a new fundamental announcement, indicating investor caution after the stock’s recent weakness. Bristol Myers Squibb Declines More Than Market
• Negative Sentiment: Unusually heavy put-option activity—44,454 contracts, approximately 71% above typical volume—signals increased near-term hedging or bearish speculation, though options activity alone does not confirm a fundamental deterioration.
• Negative Sentiment: RBC said Cytokinetics has an advantage in a patent dispute involving Bristol Myers Squibb, creating potential legal and competitive risk for BMY. Cytokinetics Has Advantage in Bristol-Myers Squibb Patent Dispute
• Negative Sentiment: Generic pressure on BMY’s legacy portfolio remains a key concern, potentially offsetting growth-brand gains and limiting enthusiasm for the shares.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on BMY shares. Roth Capital assumed coverage on shares of Bristol Myers Squibb in a research report on Wednesday, August 5th. They issued a “buy” rating and a $75.00 price objective on the stock. HSBC restated a “hold” rating and issued a $65.00 price target (up from $60.00) on shares of Bristol Myers Squibb in a research note on Thursday. Piper Sandler initiated coverage on Bristol Myers Squibb in a report on Wednesday, August 5th. They set an “overweight” rating on the stock. Raymond James Financial assumed coverage on Bristol Myers Squibb in a report on Wednesday, August 5th. They issued a “strong-buy” rating for the company. Finally, Sanford C. Bernstein upgraded Bristol Myers Squibb from a “market perform” rating to an “outperform” rating in a research report on Wednesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $66.33.

Bristol Myers Squibb Stock Down 1.0%

BMY stock opened at $63.76 on Friday. The firm has a market cap of $130.25 billion, a PE ratio of 14.04, a P/E/G ratio of 0.31 and a beta of 0.23. Bristol Myers Squibb Company has a 12 month low of $42.52 and a 12 month high of $68.64. The company has a debt-to-equity ratio of 1.89, a current ratio of 1.53 and a quick ratio of 1.38. The firm has a 50 day simple moving average of $63.50 and a 200 day simple moving average of $60.05.

Bristol Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.60 by $0.44. The firm had revenue of $12.97 billion for the quarter, compared to analyst estimates of $11.74 billion. Bristol Myers Squibb had a net margin of 18.87% and a return on equity of 66.90%. The firm’s quarterly revenue was up 5.7% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.46 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. Equities research analysts forecast that Bristol Myers Squibb Company will post 6.95 earnings per share for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, August 3rd. Investors of record on Thursday, July 2nd were given a $0.63 dividend. The ex-dividend date was Thursday, July 2nd. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.0%. Bristol Myers Squibb’s dividend payout ratio (DPR) is 55.51%.

Insiders Place Their Bets

In related news, SVP Phil M. Holzer sold 500 shares of Bristol Myers Squibb stock in a transaction dated Tuesday, August 25th. The stock was sold at an average price of $67.50, for a total value of $33,750.00. Following the transaction, the senior vice president owned 16,862 shares of the company’s stock, valued at approximately $1,138,185. This trade represents a 2.88% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 0.05% of the company’s stock.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company that discovers, develops and commercializes prescription medicines. Its portfolio includes therapies for cancer, blood disorders, cardiovascular disease, immune-mediated conditions and psychiatric disorders. Key products include Opdivo and Yervoy for oncology, Eliquis for reducing the risk of stroke and systemic embolism, Revlimid for certain blood cancers, and several other specialty medicines.

The company serves patients and healthcare providers in markets around the world, with operations and commercial activities spanning North America, Europe, Asia-Pacific and other international regions.